Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling

Genes Chromosomes and Cancer

Volumn 50, Issue 4, 2011, Pages 263-274

  Chiaretti, Sabina ^a   Tavolaro, Simona ^a   Marinelli, Marilisa ^a   Messina, Monica ^a   Del Giudice, Ilaria ^a   Mauro, Francesca Romana ^a   Santangelo, Simona ^a   Piciocchi, Alfonso ^b   Peragine, Nadia ^a   Truong, Sim ^c   Patten, Nancy ^c   Ghia, Emanuela Maria ^a   Torrente, Isabella ^d   De Propris, Maria Stefania ^a   Nanni, Mauro ^a   Lawrence, Jeff ^c   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Data Center   (Italy)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CHRONIC LYMPHATIC LEUKEMIA; CORRELATION ANALYSIS; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT MUTATION; PROGNOSIS; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79851477833     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20852     Document Type: Article

References (46)

1. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J, Taylor AM, Fegan C, Moss P, Stankovic T. 2005. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106: 3175-3182.
2. Caligaris-Cappio F, Hamblin TJ. 1999. B-cell chronic lymphocytic leukemia: A bird of a different feather. J Clin Oncol 17: 399-408.
3. Castellví-Bel S, Sheikhavandi S, Telatar M, Tai LQ, Hwang M, Wang Z, Yang Z, Cheng R, Gatti RA. 1999. New mutations, polymorphisms, and rare variants in the ATM gene detected by a novel SSCP strategy. Hum Mutat 14: 156-162.
4. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. 1998. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 91: 4342-4349.
5. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. 2003. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 1764-1775.
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. 1999. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
7. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR. 2001. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97: 587-600.
8. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C. 2009. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23: 117-124.
9. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichteret P. 1995. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589.
10. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
11. Dumont P, Leu JI, Della Pietra AC, III, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
12. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
13. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW. 1993. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459.
14. Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A. 2008. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 47: 781-793.
15. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. 1991. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417.
16. Gentile M, Mauro FR, Calabrese E, De Propris MS, Giammartini E, Mancini F, Milani ML, Guarini A, Foa R. 2005a. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: A single institute experience. Br J Haematol 130: 549-557.
17. Gentile M, Mauro FR, Guarini A, Foa R. 2005b. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol 17: 597-604.
18. Greig AV, Linge C, Terenghi G, McGrouther DA, Burnstock G. 2003. Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes. J Investig Dermatol 120: 1007-1015.
19. Guarini A, Gaidano G, Mauro FR, Capello D, Mancini F, De Propris MS, Mancini M, Orsini E, Gentile M, Breccia M, Cuneo A, Castoldi G, Foa R. 2003. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 102: 1035-1041.
20. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R. 2010. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 28: 2529-2537.
21. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854.
22. Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, Stratowa C, Abseher R. 2004. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 22: 3937-3949.
23. Jackson RS, II, Cho YJ, Liang P. 2006. TIS11D is a candidate pro-apoptotic p53 target gene. Cell Cycle 5: 2889-2893.
24. Kochethu G, Delgado J, Pepper C, Starczynski J, Hooper L, Krishnan S, Fegan C, Pratt G. 2006. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 30: 1113-1118.
25. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S. 2002. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100: 1410-1416.
26. Lahiri O, Harris S, Packham G, Howell M. 2007. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet 179: 36-44.
27. Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-16.
28. Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98: 31-36.
29. Montserrat E. 2006. New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program 2006: 279-284.
30. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. 2002. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100: 1177-1184.
31. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. 2004. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351: 893-901.
32. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De Paoli L, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G. 2009. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 15: 995-1004.
33. Rozman C, Montserrat E. 1995. Chronic lymphocytic leukemia. N Engl J Med 333: 1052-1057.
34. Sasaki Y, Negishi H, Koyama R, Anbo N, Ohori K, Idogawa M, Mita H, Toyota M, Imai K, Shinomura Y, Tokino T. 2009. p53 family members regulate the expression of the apolipoprotein D gene. J Biol Chem 284: 872-883.
35. Simon R, Lee YJ. 1982. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep 66: 37-42.
36. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, Keenan RD, Moss PA, Taylor AM. 2002. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 99: 300-309.
37. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell CR, Alvi AJ, Austen B, Weston VJ, Fegan C, Byrd PJ, Moss PA, Taylor AM. 2004. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103: 291-300.
38. Stumpo DJ, Broxmeyer HE, Ward T, Cooper S, Hangoc G, Chung YJ, Shelley WC, Richfield EK, Ray MK, Yoder MC, Aplan PD, Blackshear PJ. 2009. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 114: 2401-2410.
39. Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. 2005. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5: 105.
40. Vousden KH, Lu X. 2002. Live or let die: The cell's response to p53. Nat Rev Cancer 2: 594-604.
41. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. 1994. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157.
42. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. 2003. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951.
43. Zenz T, Häbe S, Denzel T, Winkler D, Hallek M, Hensel M, Lengfelder E, Dreger P, Jäger U, Döhner H, Stilgenbauer S. 2008a. The activity of Alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL: Final analysis from the CLL2H study of the GCLLSG. Ann Oncol 19:iv192-196 (Abstract no. 376): 204-206.
44. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwänen C, Döhner H, Stilgenbauer S. 2008b. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112: 3322-3329.
45. Zenz T, Benner A, Döhner H, Stilgenbauer S. 2008c. Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle 7: 3810-3814.
46. Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S. 2009. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113: 3801-3808.